IS2670B - Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun - Google Patents
Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnunInfo
- Publication number
- IS2670B IS2670B IS7296A IS7296A IS2670B IS 2670 B IS2670 B IS 2670B IS 7296 A IS7296 A IS 7296A IS 7296 A IS7296 A IS 7296A IS 2670 B IS2670 B IS 2670B
- Authority
- IS
- Iceland
- Prior art keywords
- cop
- vaccines
- treatment
- tyr
- glu
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
- 208000026072 Motor neurone disease Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33613901P | 2001-12-06 | 2001-12-06 | |
| PCT/IL2002/000979 WO2003047500A2 (en) | 2001-12-06 | 2002-12-05 | Vaccine and method for treatment of motor neurone diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IS7296A IS7296A (is) | 2004-06-03 |
| IS2670B true IS2670B (is) | 2010-09-15 |
Family
ID=23314742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7296A IS2670B (is) | 2001-12-06 | 2004-06-03 | Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7351686B2 (is) |
| EP (1) | EP1429800B1 (is) |
| JP (1) | JP4542339B2 (is) |
| KR (1) | KR20040081431A (is) |
| CN (2) | CN102151330B (is) |
| AT (1) | ATE422362T1 (is) |
| AU (1) | AU2002353486B2 (is) |
| CA (1) | CA2469092C (is) |
| CY (1) | CY1109044T1 (is) |
| DE (1) | DE60231131D1 (is) |
| DK (1) | DK1429800T3 (is) |
| ES (1) | ES2322566T3 (is) |
| HU (1) | HU228207B1 (is) |
| IL (1) | IL160105A0 (is) |
| IS (1) | IS2670B (is) |
| MX (1) | MXPA04005537A (is) |
| NO (1) | NO336231B1 (is) |
| NZ (1) | NZ533356A (is) |
| PL (1) | PL205469B1 (is) |
| PT (1) | PT1429800E (is) |
| RU (1) | RU2303996C2 (is) |
| SI (1) | SI1429800T1 (is) |
| WO (1) | WO2003047500A2 (is) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399740B2 (en) | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
| AU2004203772B2 (en) * | 2003-01-07 | 2009-07-16 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| WO2005056574A2 (en) | 2003-12-09 | 2005-06-23 | Yeda Research And Development Co. Ltd. | Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| EP1684797A1 (en) | 2003-11-12 | 2006-08-02 | Yeda Research and Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| WO2005084377A2 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| MXPA06012864A (es) * | 2004-05-07 | 2007-07-18 | Peptimmune Inc | Metodo de tratamiento de enfermedades con copolimeros aleatorios. |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| EP1910827A4 (en) * | 2005-07-15 | 2010-02-03 | Novartis Ag | MOLECULAR MOTIVES ASSOCIATED WITH PATHOGENS (PAMP) |
| CN100448481C (zh) * | 2006-06-22 | 2009-01-07 | 中国科学院遗传与发育生物学研究所 | xCT蛋白及其编码基因的新用途 |
| EP2195008A1 (en) | 2007-09-24 | 2010-06-16 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| US8709433B2 (en) | 2010-10-11 | 2014-04-29 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2013084236A1 (en) * | 2011-12-05 | 2013-06-13 | Ben-Gurion University Of The Negev Research And Development Authority | Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als) |
| EP2831584B1 (en) * | 2012-03-26 | 2020-06-17 | Yeda Research and Development Co., Ltd. | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
| WO2014037952A1 (en) | 2012-09-10 | 2014-03-13 | Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| LT3506921T (lt) | 2016-08-31 | 2023-08-10 | Mapi Pharma Ltd | Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3849650A (en) | 1973-03-29 | 1974-11-19 | Picker Corp | Automatic x-ray inspection system |
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| SE505316C2 (sv) * | 1995-10-17 | 1997-08-04 | Kenneth G Haglid | Användning av proteinet S-100b för framställning av läkemedel för nervceller |
| RU2211697C2 (ru) * | 1996-09-27 | 2003-09-10 | Гилфорд Фармасьютикалз Инк. | Способ лечения глутаматных расстройств |
| KR20010052170A (ko) * | 1998-02-13 | 2001-06-25 | 오토이뮨, 인코포레이티드 | ＣＯＰ-1 및 Ｔｈ2-증진 시토킨류를 이용한 다발성경화증의 치료 방법 |
| US20030108528A1 (en) * | 1998-05-19 | 2003-06-12 | Michal Eisenbach-Schwartz | Activated t-cells, nervous system-specific antigens and their uses |
| US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| WO1999060021A2 (en) | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co. Ltd. | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| EP1039929A1 (en) | 1998-07-21 | 2000-10-04 | YEDA RESEARCH AND DEVELOPMENT Co. Ltd. | Activated t-cells and their uses |
| IL140592A0 (en) | 1998-07-23 | 2002-02-10 | Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| RU2155063C1 (ru) * | 1999-10-20 | 2000-08-27 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения |
| HK1054507B (zh) * | 2000-01-20 | 2008-10-31 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 |
| IL150801A0 (en) * | 2000-06-07 | 2003-02-12 | Yeda Res & Dev | The use of copolymer 1 and related peptides and polypeptides for protecting central nervous system cells from glutamate toxicity |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US6835711B2 (en) * | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| US7399740B2 (en) * | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
-
2002
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 EP EP02788511A patent/EP1429800B1/en not_active Expired - Lifetime
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/en not_active Ceased
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko not_active Ceased
- 2002-12-05 CA CA2469092A patent/CA2469092C/en not_active Expired - Fee Related
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
-
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
-
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS2670B (is) | Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun | |
| MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
| WO2002009746A8 (en) | Vaccines comprising outer membrane vesciles from gram negative bacteria | |
| IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
| ATE383375T1 (de) | Wti-modifiziertes peptid | |
| DE60239707D1 (de) | Antimikrobielle kationische peptide und diese enthaltende formulierungen | |
| HK1052301A1 (zh) | α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途 | |
| DE60233898D1 (de) | Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln | |
| BR9610679A (pt) | Antígenos de leishmania para uso na terapia e disgnose da leishmaniose | |
| MXPA02005563A (es) | Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma. | |
| EP1958960A3 (en) | A process for the preparation of a non-toxic anthrax vaccine | |
| BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
| EP1471936A4 (en) | HIV VACCINE AND METHOD OF USE | |
| MXPA02010173A (es) | Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis. | |
| ATE515258T1 (de) | Mukosales verabreichungssytem | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| UY27373A1 (es) | Formulaciones de interferón beta-humano | |
| MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
| DK1268522T3 (da) | LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler | |
| WO1998035045A3 (en) | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis | |
| WO2002098359A3 (en) | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis | |
| IT1277926B1 (it) | Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire | |
| CA2394843A1 (en) | A vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias | |
| BR0303384A (pt) | Citalopram e seus usos no tratamento de pressão sanguìnea elevada | |
| RU2350351C2 (ru) | Композиции и лекарственные формы на основе гастрина, методы применения и получения |